Provisions in this LCD and related coding article only address Vertebral
Augmentation for Osteoporotic Vertebral Compression Fracture (VCF). Coverage
will remain available for medically necessary procedures for other conditions
not included in this LCD.

PVA (percutaneous vertebroplasty (PVP) or kyphoplasty (PKP)) is covered in
patients with **BOTH** the following:

  1. Inclusion criteria **(ALL are required)** : 
    1. Acute (< 6 weeks) or subacute (6-12 weeks) osteoporotic VCF (T1 - L5), based on symptom onset, and documented by advanced imaging (bone marrow edema on MRI or bone-scan/SPECT/CT uptake) (1-3,10,25,27)
    2. Symptomatic ( **ONE** ): 
      1. Hospitalized with severe pain (Numeric Rating Scale (NRS) or Visual Analog Scale (VAS) pain score  8) (4-7)
      2. Non-hospitalized with moderate to severe pain (NRS or VAS 5) despite optimal non-surgical management (NSM) (10) ( **ONE** ): 
        1. Worsening pain
        2. Stable to improved pain (but NRS or VAS still 5) **(with  2 of the following):**
          1. Progression of vertebral body height loss
          2. > 25% vertebral body height reduction
          3. Kyphotic deformity
          4. Severe impact of VCF on daily functioning (Roland Morris Disability Questionnaire (RDQ) >17
    3. Continuum of care (10) **(Both)**  
      1. All patients presenting with VCF should be referred for evaluation of BMD and osteoporosis education for subsequent treatment as indicated.
      2. All patients with VCF should be instructed to take part in an osteoporosis prevention/treatment program.
  2. Exclusion criteria (2,5,8-10) **(Can have NONE of the following)** :  

    1. Absolute contraindication 
      1. Current back pain is not primarily due to the identified acute or subacute VCF(s).
      2. Osteomyelitis, discitis, active systemic or surgical site infection
      3. Pregnancy
    2. Relative contraindication 
      1. Greater than three vertebral fractures per procedure
      2. Allergy to bone cement or opacification agents
      3. Uncorrected coagulopathy
      4. Spinal instability
      5. Myelopathy from the fracture
      6. Neurologic deficit
      7. Neural impingement
      8. Fracture retropulsion/canal compromise



Osteoporosis (and low bone mass) affects 50 percent of people over 50 years of
age, or over 50 million people in the United States. Its primary impact,
fractures (also called fragility or low-trauma fractures), occurs secondary to
normal activity (e.g., bending, coughing, lifting, fall from a standing
height), and eventually occurs in 50% of women and 20% of men. VCFs constitute
one-quarter of osteoporotic fractures (6), often at the midthoracic (T7-T8)
and thoracolumbar junction (T12-L1). They may cause significant acute and
chronic pain, leading to complications of impaired mobility comparable to a
hip fracture (pneumonia, loss of bone and muscle mass, incidental falls, deep
venous thrombosis, depression, and isolation) (10). Medicare claims data shows
an 85% 10 year mortality following a VCF diagnosis (11). Under-diagnosis and
under-treatment may exacerbate morbidity and mortality (10).

Treatment options for symptomatic osteoporotic VCF range from NSM (anti-
osteoporosis therapy, analgesics, limited activity/bed rest, back brace,
physical therapy) to PVA (PVP and PKP). PVP involves the percutaneous
injection of bone cement under image guidance into the VCF. PKP adds balloon
tamponade within the fractured vertebral body to create a low pressure cavity
prior to cement injection. Both treatments aimed to immobilize the fracture,
reduce pain, and improve alignment.

Successful small European series introduced PVP into the United States in
1993; by 2007 encouraging preliminary observational data led to medical
society endorsement and clinical acceptance in painful osteoporotic VCFs
refractory to medical management. Subsequent early open-label randomized
controlled trials (RCTs), including the Vertebroplasty for Painful Chronic
Osteoporotic Vertebral Fractures (VERTOS) trial (21), the Fracture Reduction
Evaluation (FREE) trial (22, 23), VERTOS II (14), and others, found a benefit
of vertebral augmentation over non-surgical management.

VERTOS II was a multicenter RCT that compared PVP and NSM of acute (< 6 weeks)
osteoporotic VCF in patients with moderate to severe pain (VAS  5) (14).
Among 202 patients, the primary endpoint of pain relief at one month and one
year was greater after PVP (-5.2/-5.7) than after NSM (-2.7/-3.7) (p < 0.001).
Secondary outcomes, including RDQ and Quality of Life Questionnaire of the
European Foundation for Osteoporosis (QUALEFFO), were similarly improved. The
main limitation in the VERTOS II trial was the lack of blinding. Subsequent
analysis of the medical cohort showed that 60% achieved sufficient (VAS  3)
pain relief, most within 3 months (15). The authors acknowledged that despite
the VERTOS II results, "clinicians still do not know how to best treat their
patients," but conclude that, pending further RCTs, PVP may be justified in
patients with insufficient pain relief after 3 months of conservative
treatment (15).

The lack of blinding made the early open-label RCTs, vulnerable to placebo
effect. However, in 2009, two high profile, methodologically controversial
(e.g., non-rigorous patient selection) double-blinded, RCTs found no benefit
of PVP over a "sham" procedure (pedicle periosteal bupivacaine injection)
(12,13). Ever since, there has been a lack of consensus on the appropriate
management of osteoporotic VCF, particularly the role of PVA (6,10). Medicare
claims data shows that among over 2 million VCF patients, PVA was performed in
20% in 2005, peaked at 24% in 2007-2008, and declined to 14% in 2014, a 42%
decrease (11). Lower PVA utilization was associated with a 4% increase in
propensity-adjusted mortality risk (p < 0.001). A secondary analysis gave a
number needed to treat (NNT) at one year to save a life of 22.8 and 14.8 for
vertebroplasty and kyphoplasty, respectively (26). Both studies noted the
potential for selection bias despite propensity scoring. Subsequent major
RCTs, described below, have attempted to address the perceived shortcomings of
these two negative studies (primarily more stringent selection criteria and
choice of control).

The Vertebroplasty for Acute Painful Osteoporotic Fractures (VAPOUR) double-
blinded RCT was designed to compare acute fracture (< 6 weeks) PVP with a sham
procedure (subcutaneous, not periosteal, infiltration) for patients with
severe pain (NRS  7) (5). Among 120 randomized patients, the primary endpoint
(NRS score < 4 by 14 days) was achieved in 44% and 21% of PVP and sham
patients, respectively (p = 0.011), and durable to 6 months. Mean height loss
at 6 months was 36% greater in the control group (63% vs. 27%). Hospital
inpatients constituted 57% of study patients; among this group, median length
of stay was reduced by 5.5 days in the PVP group. In addition to a focus on
the acute, severely painful VCF, this study also concentrated on delivering
greater cement volumes than prior studies. The authors conclude that PVP is
superior to true placebo control of severe pain in VCFs of less than 6 weeks.

VERTOS IV used the same inclusion criteria as VERTOS II, but was a double-
blinded comparison of PVP with a sham procedure (pedicle periosteal
infiltration) (7). Among the 180 randomized patients, although the reduction
in VAS score was clinically (> 1.5 points) and statistically significant up to
12 months in both groups (5.00 at 12 months in the PVP group vs. 4.75 in the
sham group), reductions in VAS scores did not differ between groups (p =
0.48). The authors conclude, "the results suggest that periosteal infiltration
alone in the early phase provides enough pain relief with no need for
additional cementation." They recommend the "pragmatic approach" of first use
of "periosteal infiltration during natural healing" and "cementation only in a
selected subgroup of patients with insufficient pain relief after this early
phase." They also highlight a subgroup that may warrant earlier PVP per the
VAPOUR trial (hospital inpatients with more comorbidity and severe pain).

The 2018 multicenter, prospective, uncontrolled, EVOLVE study of 354 Medicare-
age patients with acute or subacute ( 4 mo.) painful (NRS  7) VCF (all but 8
osteoporotic), found statistical improvement in NRS, Oswestry Disability Index
(ODI), Short Form-36 Questionnaire Physical Component Summary (SF-36v2 PCS),
and EuroQol-5-Domain (EQ-SD) out to 12 months (24). The authors conclude that
"kyphoplasty is a safe, effective, and durable procedure for treating patients
with painful VCF due to osteoporosis."

Whether or when to use PVA for osteoporotic VCF has been very controversial
since publication of the two negative 2009 RCTs. At the time, some national
organizations withdrew (Australia Medical Services Advisory Committee) (6) or
severely curbed (American Academy of Orthopaedic Surgeons) (16) endorsement.
Others continued recommending PVA in select patients. The National Institute
for Health and Care Excellence (NICE) recommends PVA in patients "who have
severe ongoing pain after a recent, unhealed vertebral fracture despite
optimal pain management and in whom the pain has been confirmed to be at the
level of the fracture by physical examination and imaging" (4). In a 2014
consensus statement, the Society of Interventional Radiology (SIR), American
Association of Neurological Surgeons (AANS), Congress of Neurological Surgeons
(CNS), American College of Radiology (ACR), American Society of Neuroradiology
(ASNR), American Society of Spin Radiology (ASSR), Canadian Interventional
Radiology Association (CIRA), and the Society of NeuroInterventional Surgery
(SNIS) considered PVA a proven medically appropriate therapy for treatment of
painful VCFs refractory to brief (24 hrs.) nonoperative medical therapy (1).
The 2017 Cardiovascular and Interventional Radiologic Society of Europe
(CIRSE) guideline notes that while the evidence for PVP has been conflicting,
based on recent data "it seems clear that PVP offers significant pain
reduction in patients with acute VCFs after short (<3 wks.) failed medical
therapy (2).

A 2018 Cochrane review of 21 trials of PVA for osteoporotic VCF "does not
support a role for vertebroplasty for treating acute or subacute osteoporotic
vertebral fractures in routine practice (17)," though its methodology has been
criticized (25). A 2019 systematic review and meta-analysis by the American
Society for Bone and Mineral Research (ASBMR) Task Force concluded:
"Vertebroplasty does not work to relieve pain from the fracture, and
kyphoplasty should generally only be done in the context of a placebo-
controlled clinical trial" (20). Based on the uncertainty of benefit, citing
both the recent Cochrane analysis and the VERTOS IV results, UpToDate
recommends reserving PVA "for patients with incapacitating pain from acute and
subacute VCFs who are unable to taper parenteral opioids or transition to oral
opioids within seven days of admission or have intolerable side effects from
opioid therapy" (8).

The benefit of PVA is supported by the significantly higher 5-year mortality
risk for VCF in Medicare patients after a decline in utilization (11). In a
recent systematic review of evidence-based guidelines for the management of
osteoporotic VCF, three of four guidelines recommended PVA (19). In 2018, a
multispecialty expert panel (orthopedic and neurosurgeons, interventional
[neuro] radiologists and pain specialists), endorsed vertebral augmentation
for select patients, in a clinical care pathway (developed using the RAND/UCLA
Appropriateness Method), based on seven variables (pain duration and
evolution, acute fracture by advanced imaging, kyphotic deformity, degree and
progression of vertebral height loss, and impact on daily functioning) (10).
Whether subgroups of patients might benefit more from vertebroplasty or
kyphoplasty, requires further study (6). A review of the 14 published RCTs
that examined the role of VA in osteoporotic VCF concluded: "While the RCT
data are conflicting, there are patients with acute fractures causing
significant pain and disability who can derive benefit with respect to
improvement in pain outcomes, reduction in narcotic usage and reduced length
of hospital stay" (27). In a meta-analysis of 16 studies with mortality as an
outcome, eight reported mortality benefit in VA, seven reported no benefit,
and one reported mixed results (28). The analysis found that VA provided a 22%
mortality benefit over NSM at 10 years. However, the authors note the
potential for "a strong selection bias in the selection of healthier patients
for VA that was not captured by the analysis." They conclude that VA "remains
a controversial treatment" and "should be offered in carefully selected
patients."

In summary, the premise of weight-bearing fracture immobilization, to limit
pain and deformity, has prima facie validity on first principles. Superimposed
is the recent trend toward immediate, focused, surgical immobilization, and
away from prolonged, general immobilization (e.g., casting, bracing, bedrest)
and prolonged systemic pain management (e.g., opioid analgesics), particularly
in the elderly. The preponderance of evidence (studies, national and society
guidelines, systematic reviews, multispecialty panel clinical care pathway,
and Medicare claims data) favors consideration of early PVA in select patients
(moderate to severe and disabling pain due to acute osteoporotic VCF confirmed
by physical examination and advanced imaging findings). However, in addition
to timely fracture treatment, also warranted is increased emphasis on ensuring
the continuum of care, and preventing medical undertreatment of the
overarching systemic disease, of which VCF is a symptom (29).